BDBM450248 US10676431, Example 12::US10676431, Example 22::US11117861, Example 22

SMILES CC(N)c1cccc(c1)-c1ccc(N2CC[C@@H](NC(=O)Nc3ccc(Cl)cc3)C2=O)c(F)c1F

InChI Key InChIKey=BWZHJIDEGQMYEJ-UHFFFAOYSA-N

Data  8 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 450248   

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450248(US10676431, Example 22 | US10676431, Example 12 | ...)
Affinity DataEC50:  2.5nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450248(US10676431, Example 22 | US10676431, Example 12 | ...)
Affinity DataEC50:  450nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450248(US10676431, Example 22 | US10676431, Example 12 | ...)
Affinity DataEC50:  33nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450248(US10676431, Example 22 | US10676431, Example 12 | ...)
Affinity DataEC50:  1.50E+3nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450248(US10676431, Example 22 | US10676431, Example 12 | ...)
Affinity DataEC50:  2.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450248(US10676431, Example 22 | US10676431, Example 12 | ...)
Affinity DataEC50:  450nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450248(US10676431, Example 22 | US10676431, Example 12 | ...)
Affinity DataEC50:  33nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450248(US10676431, Example 22 | US10676431, Example 12 | ...)
Affinity DataEC50:  1.50E+3nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
Go to US Patent